LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Search

Simulations Plus Inc

Gesloten

SectorGezondheidszorg

19.19 1.43

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

19.05

Max

19.5

Belangrijke statistieken

By Trading Economics

Inkomsten

67M

-681K

Verkoop

-2.9M

17M

K/W

Sectorgemiddelde

48.528

78.892

EPS

-0.034

Dividendrendement

0.48

Winstmarge

-3.9

Werknemers

212

EBITDA

327K

5.3M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+6.05% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.48%

2.38%

Volgende Winsten

8 jan 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

45M

390M

Vorige openingsprijs

17.76

Vorige sluitingsprijs

19.19

Nieuwssentiment

By Acuity

50%

50%

164 / 374 Rangschikking in Healthcare

Simulations Plus Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 dec 2025, 21:41 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 dec 2025, 14:57 UTC

Acquisities, Fusies, Overnames

Accenture to Acquire Cabel Industry from Fibonacci Group

24 dec 2025, 12:48 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead

24 dec 2025, 12:21 UTC

Belangrijke Marktbewegers

Nike Shares Tick Up After Apple CEO Tim Cook Buys $2.9 Million of Its Stock

24 dec 2025, 22:22 UTC

Acquisities, Fusies, Overnames

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dec 2025, 19:35 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 dec 2025, 19:35 UTC

Marktinformatie

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie
Acquisities, Fusies, Overnames

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dec 2025, 19:06 UTC

Marktinformatie

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 dec 2025, 19:03 UTC

Marktinformatie

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 dec 2025, 17:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

24 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

24 dec 2025, 17:08 UTC

Acquisities, Fusies, Overnames

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec 2025, 16:53 UTC

Acquisities, Fusies, Overnames

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 dec 2025, 16:31 UTC

Marktinformatie
Acquisities, Fusies, Overnames

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 dec 2025, 16:28 UTC

Acquisities, Fusies, Overnames

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 dec 2025, 16:17 UTC

Marktinformatie

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 dec 2025, 15:33 UTC

Acquisities, Fusies, Overnames

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 dec 2025, 15:30 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec 2025, 15:19 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec 2025, 14:49 UTC

Acquisities, Fusies, Overnames

Mexico's Ollamani Sells Stake in Azteca Stadium

24 dec 2025, 14:19 UTC

Marktinformatie

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 dec 2025, 14:08 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec 2025, 14:06 UTC

Marktinformatie

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 dec 2025, 13:24 UTC

Marktinformatie

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 dec 2025, 12:59 UTC

Acquisities, Fusies, Overnames

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec 2025, 12:51 UTC

Acquisities, Fusies, Overnames

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

24 dec 2025, 12:38 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

Peer Vergelijking

Prijswijziging

Simulations Plus Inc Prognose

Koersdoel

By TipRanks

6.05% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20.5 USD  6.05%

Hoogste 25 USD

Laagste 16 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Simulations Plus Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Sentiment

By Acuity

164 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat